Barata, Pedro C.
Mendiratta, Prateek
Heald, Brandie
Klek, Stefan
Grivas, Petros
Sohal, Davendra P. S.
Garcia, Jorge A.
Article History
First Online: 4 July 2018
Compliance with Ethical Standards
:
: No external funding was used in the preparation of this manuscript.
: Brandie Heald has disclosed to be on an advisory board for Invitae and the speakers’ bureau for Myriad Genetics Laboratory. Dr. Petros Grivas has disclosed to be a consultant or advisor for Foundation Medicine, Genentech, Dendreon, Bayer, Driver Inc., Exelixis, Merck & Co., Bristol-Myers Squibb, AstraZeneca, Biocept, Clovis Oncology, EMD Serono, and Seattle Genetics; has received research funding from Mirati Therapeutics, Genentech/Roche, Merck, Oncogenex, Bayer, Pfizer, and AstraZeneca. Dr. Davendra Sohal has disclosed to be a consultant or advisor for Perthera and Foundation Medicine, and received research funding from Novartis, Celgene, OncoMed, Bayer, and Genentech/Roche. Dr. Jorge Garcia has disclosed to be a consultant or advisor for Sanofi, Pfizer, Bayer, Eisai, Exelexis, Medivation/Astellas, and Genentech/Roche; has received research funding from Pfizer, Astellas Pharma, Orion Pharma GmbH, Bayer, Janssen Oncology, Genentech/Roche, and Lilly. Pedro C. Barata, Prateek Mendiratta, and Stefan Klek declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.